# V1 Empirics Check — x-ai/grok-4.1-fast (Variant C)

**Model:** x-ai/grok-4.1-fast
**Variant:** C
**Date:** 2026-03-22T17:08:45.403308

---

### 1. Idea Fidelity
The paper faithfully pursues the original idea manifest. It exploits the staggered transposition of Directive 2019/1023 across 26 EU countries using Eurostat sts_rb_q quarterly bankruptcy data (2015–2025, ~1,037 observations), Callaway-Sant'Anna DiD with 6–7 pre-periods, event studies (8 pre/12 post quarters), COVID stringency controls, and sector decompositions (industry B–E, construction F, aggregate B–S). Minor deviations include slightly adjusted transposition dates (e.g., Germany January 2021 vs. December 2020 in manifest), omission of the promised business registrations compositional check, and addition of late transpositions (e.g., Poland December 2023). No key elements of identification, data, or research question (preventive restructuring vs. bankruptcy reduction, rescue vs. reclassification) are missed.

### 2. Summary
This paper provides the first causal evaluation of the EU Preventive Restructuring Directive (2019/1023), exploiting staggered national transpositions across 26 countries to estimate its impact on quarterly bankruptcy declarations via Callaway-Sant'Anna DiD. It finds a precisely estimated null effect (aggregate ATT = 0.10, SE = 0.25 on log(index + 1)), robust across specifications, sectors, and placebo tests, favoring a "reclassification hypothesis" over firm rescue. The result challenges Commission claims of large-scale firm/job savings and informs ongoing legislative review.

### 3. Essential Points
1. **Pre-trends in event study require stronger validation.** Table 3 shows two significant pre-treatment coefficients (t−8: 0.174∗, t−7: −0.217∗ under simultaneous CIs), and a massive outlier at t+9 (1.846∗∗∗). The text dismisses pre-trends as "Type I error over 21 tests," but with only 26 countries/11 cohorts, this risks underpowered tests and masking heterogeneity. Authors must provide graphical event study plots (with 90%/95% CIs), test for trend differences formally (e.g., joint pre-trend F-test), and report cohort-specific ATTs to confirm parallel trends hold conditionally.

2. **Transposition dates and treatment coding need verification.** Minor date discrepancies (e.g., Germany StaRUG January vs. manifest December 2020; Belgium/Poland added as 2023 laggards) could bias timing. Late cohorts (e.g., post-2023) have <4 post-quarters in 2025 data, inflating post-period weights toward early adopters. Provide a full table of exact entry-into-force dates (with EUR-Lex citations), sensitivity to alternative codings (e.g., announcement vs. force), and cohort-time ATTs excluding post-2022 cohorts.

3. **Absence of compositional controls undermines mechanism claims.** The manifest promised business registrations as a check for reclassification (filings shifting categories vs. genuine reduction); this is missing. Without it (or insolvency composition data), the null cannot distinguish reclassification from power issues or offsets (e.g., informal workouts rising). Add this check or microdata on proceeding types; otherwise, mute strong claims favoring reclassification over rescue/stigma.

### 4. Suggestions
The paper is well-structured for AER: Insights, with crisp writing, novel quasi-experiment, and a clear null result that is economically meaningful (ruling out >30% reductions, contra Commission projections). Magnitudes are plausible—null on a normalized index amid post-COVID surges (mean 137 pre- vs. 154 post-) aligns with institutional inertia in legal transplants. Standard errors are appropriate given 26 country clusters (conservative for DiD), though small N warrants the robustness suite (Poisson, levels, drops). Sign instability across forms (positive log, negative level/Poisson) credibly signals zero effect. To elevate to publication:

- **Visuals and diagnostics (priority).** Replace table-only event studies with figures: (i) aggregate dynamic plot vs. never-treated synthetic control; (ii) cohort-specific ATTs (stacked by transposition wave); (iii) raw index time series by early/mid/late cohorts, overlaid with transposition bars and COVID stringency. Add parallel trends tests (e.g., Roth et al. 2023 pre-trend estimator) and variance weights from CS (to flag never-treated dominance).

- **Data and balance.** Tabulate pre-trends by covariate (e.g., GDP growth, firm entry rates from Eurostat bd_hgnace_r, debt/GDP) across cohorts. Include Ireland explicitly (even if imputed/excluded) or justify. Report CS aggregation weights (e.g., % from 2021 vs. 2023 cohorts) and power calculations (e.g., minimal detectable effect ~25% given SD=99, aligns with CI). Extend to 2025Q4 forecasts if data-limited, but sensitivity to 2024-only post-periods.

- **Heterogeneity and mechanisms.** Exploit manifest sectors fully: estimate CS-DiD by NACE (B–E, F, G–N, aggregate) with sector×cohort interactions; construction's large point estimate (0.45) hints at industry variation—test if tradable sectors (less bank-dependent) show stronger nulls. Add promised business registrations (sts_rnb_q or demography data) as placebo outcome: null there supports no compositional shift. Explore treatment intensity: code pre-existing frameworks (e.g., binary for France/Germany/Netherlands) and interact; triple-difference with World Bank RFI index changes.

- **Robustness expansions.** (i) Sun-Abraham (2021) estimator for comparison; (ii) entropy balancing on pre-trends; (iii) synthetic controls (Abadie et al. 2010) weighting never-treated optimally; (iv) binned cohorts (3–4 groups) to mitigate late-cohort thinness. Placebo on pre-2020 reforms (e.g., Germany's 2012 ESUG). Control interactions: stringency×Post, or leads/lags.

- **Economic calibration and discussion.** Translate to levels: e.g., 10% log-shift on index=137 implies ~14 extra declarations/quarter/country (plausible null vs. Commission's 200k/year). Standardized effects (Appendix Table 4) are useful—extend to all specs. Discuss power tradeoffs: short post-periods for laggards vs. long pre (good for trends). Broaden implications: link to transplant failures (e.g., quantify "inertia" via surveys on practitioner uptake). Mechanism tests: if microdata unavailable, correlate null with national court backlogs (CEPEJ data).

- **Polish and extensions.** Fix summary stats mismatch (Table 1 mean 136.9 overall vs. text 119.1; pre/post 137/154 vs. 110/134)—reconcile. Add online appendix with full CS outputs (group-time ATTs), code/data links (Eurostat API reproducible). For bigger impact, forecast 2026–2027 effects as more post-data accrues, or extend to firm survival (annual bd_hgnace_r).

Overall, this is publishable with fixes to essentials: strong identification delivers a policy-relevant null that advances insolvency empirics beyond single-country studies.
